Drug firm Lupin today said it has launched its antibiotic Tobramycin inhalation solution in the US market.
The company has launched the product as it has received an approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a filing to BSE.
The company's Tobramycin Inhalation Solution USP, 300 mg/5 ml, is the generic version of Novartis Pharmaceuticals Corporation's Tobi 300 mg/5 ml, it added.
The product is indicated for the management of cystic fibrosis patients with P aeruginosa, Lupin said.
As per IQVIA MAT April 2018 data, Tobramycin inhalation solution USP, 300 mg/5 ml, had annual sales of nearly USD 99 million in the American market, it added.
Shares of Lupin today closed at Rs 869.60 per scrip on BSE, up 1.79 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app